Clinical Trial Update: Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluated the effects of a glucagon and glucagon-like peptide-1 co-agonist on cardiac function and metabolism in overweight adults with type 2 d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• Glucagon and GLP-1 co-agonist (investigational) (glucagon/GLP-1 dual receptor agonist)

Snippet

Sponsor: Cambridge University Hospitals NHS Foundation Trust | Conditions: Type 2 Diabetes, Obesity | Phase 4 | Status: COMPLETED